Nordson Corporation · NASDAQ:NDSN
Nordson — Merger or Acquisition (May 2024)
12 slides from Nordson's merger presentation, May 28, 2024
Slide 1: Nordson Corporation Acquires Atrion Corporation
Nordson Corporation Acquires Atrion Corporation Market leader in single-use proprietary medical infusion and niche cardiovascular technologies May 28, 2024
Slide 2: Agenda
Agenda Nordson Announces Agreement to Acquire Atrion Corporation End Market Summary Fit with Nordson Atrion Product Portfolio Transaction Summary Sundaram Nagarajan Dan Hopgood Stephen Shamrock Stephen Lovass Lara Mahoney President and EVP & Chief Accounting Officer EVP, Medical & Fluid Vice Preside
Slide 3: Additional Information for Investors and Security Holders; Forward-Looking Statements
Click Additional Information for to edit title Investors and Security Holders Forward-Looking Statements This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking stat
Slide 4: Secular Growth Drivers = Attractive Medical End Markets
Secular Growth Drivers = Attractive Medical End Markets Aging of the population / Rising chronic health conditions Increasing healthcare spending and procedure volumes Increasing adoption of minimally- invasive surgical techniques Continued innovation and medical OEM outsourcing 4
Slide 5: Highly Complementary to Nordson MEDICAL
Highly Complementary to Nordson MEDICAL 1. Adds a category leader in infusion fluid delivery and niche cardiovascular therapies 2. Highly complementary transaction which aligns closely with Nordson MEDICAL’s customer base and core competencies in precision plastics, with leverageable worldclass FDA
Slide 6: Leading brands in medical infusion fluid delivery and niche cardiovascular therapies
Leading brands in medical infusion fluid delivery and niche cardiovascular therapies ~85% single-use medical components produced in three worldclass FDA registered facilities % OF BRAND PRODUCTS SALES Single-use needle free valves for infusion Medical Fluid Delivery 43% therapies (drug administrat
Slide 7: Significantly expands Nordson's addressable market in infusion and cardiovascular therapies
Significantly expands Nordson’s addressable market in infusion and cardiovascular therapies Highly complementary with Nordson MEDICAL’s customer base and core competencies Strategic Fit Single use fluid management components Leading provider of single use Expands Nordson’s addressable market Fluid C
Slide 8: NBS Next supports operational improvement and future growth
NBS Next supports operational improvement and future growth FDA registered Highly skilled organization Strong patent portfolio design & manufacturing spaces which can leverage NBS Next & product pipeline Worldclass FDA registered facilities in Strong skills & expertise in medical Skilled engin
Slide 9: Transaction Summary
Transaction Summary Atrion 2023 Revenue $169 million and EBITDA $39 million, or 23% of sales All-cash transaction that values Atrion at $460.00 per share, or an enterprise value of Financial ~$800 million Overview Valuation of 15X FY2024 EBITDA, inclusive of synergies expected to be realized w
Slide 10: Questions & Answers
Questions & Answers Giordson
Slide 11: Additional Information and Where to Find It
Click Additional Information forto edit title Investors and Security Holders Additional Information and Where to Find It Atrion Corporation (“Atrion”) expects to file with the Securities and Exchange Commission (“SEC”) and furnish to its stockholders a proxy statement on Schedule 14A (the “Proxy Sta
Slide 12: Non-GAAP Definitions
Appendix Non-GAAP Definitions This presentation contains references to non-GAAP financial information. Although these are non-GAAP measures, we believe that they are useful to an investor in evaluating the company performance for the period presented. These non-GAAP definitions include: EBITDA is